Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study-Reference-Cited by-同舟云学术

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

Published:2011-08 Issue:9792 Volume:378 Page:667-675
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Teerlink John R,Clarke Cyril P,Saikali Khalil G,Lee Jacqueline H,Chen Michael M,Escandon Rafael D,Elliott Lyndsey,Bee Rachel,Habibzadeh Mohammad Reza,Goldman Jonathan H,Schiller Nelson B,Malik Fady I,Wolff Andrew A

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. The search for the ideal positive inotropic agent;Packer;N Engl J Med,1993

2. Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association;Lloyd-Jones;Circulation,2010

3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)

4. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond;Teerlink;Heart Fail Rev,2009

5. Cardiac inotropes: current agents and future directions;Hasenfuss;Eur Heart J,2011

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle;International Journal of Molecular Sciences;2024-09-10

2. Maturation of human cardiac organoids enables complex disease modelling and drug discovery;2024-09-09

3. Efficacy and Safety of Omecamtiv Mecarbil in Adult Patients with Heart Failure with Reduced Ejection Fraction;International Journal of Pharmacology;2024-08-01

4. Characterization of NEB pathogenic variants in patients reveals novel nemaline myopathy disease mechanisms and omecamtiv mecarbil force effects;Acta Neuropathologica;2024-04-18

5. Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin T;2024-04-09